Fragile X syndrome (FXS) is a neurodevelopmental
disorder characterized
by intellectual disabilities and a plethora of neuropsychiatric symptoms.
FXS is the leading monogenic cause of autism spectrum disorder (ASD),
which is defined clinically by repetitive and/or restrictive patterns
of behavior and social communication deficits. Epilepsy and anxiety
are also common in FXS and ASD. Serotonergic neurons directly innervate
and modulate the activity of neurobiological circuits altered in both
disorders, providing a rationale for investigating serotonin receptors
(5-HTRs) as targets for FXS and ASD drug discovery. Previously we
unveiled an orally active aminotetralin, (S)-5-(2'-fluorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine (FPT),
that exhibits partial agonist activity at 5-HT1ARs, 5-HT2CRs, and 5-HT7Rs and that reduces repetitive behaviors
and increases social approach behavior in wild-type mice. Here we
report that in an Fmr1 knockout mouse model of FXS
and ASD, FPT is prophylactic for audiogenic seizures. No FPT-treated
mice displayed audiogenic seizures, compared to 73% of vehicle-treated
mice. FPT also exhibits anxiolytic-like effects in several assays
and increases social interactions in both Fmr1 knockout
and wild-type mice. Furthermore, FPT increases c-Fos expression in
the basolateral amygdala, which is a preclinical effect produced by
anxiolytic medications. Receptor pharmacology assays show that FPT
binds competitively and possesses rapid association and dissociation
kinetics at 5-HT1ARs and 5-HT7Rs, yet has slow
association and rapid dissociation kinetics at 5-HT2CRs.
Finally, we reassessed and report FPT’s affinity and function
at 5-HT1ARs, 5-HT2CRs, and 5-HT7Rs. Collectively, these observations provide mounting support for
further development of FPT as a pharmacotherapy for common neuropsychiatric symptoms in FXS and ASD.